Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Prospektiv undersøgelse af kosttilskud til støtte for hårvækst hos kvinder

10. november 2026 opdateret af: Nutraceutical Wellness Inc.

En enkelt-center, prospektiv undersøgelse af kosttilskud til støtte for hårvækst hos kvinder med selvopfattet tyndt hår

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair.

Studieoversigt

Detaljeret beskrivelse

A single site open label interventional study evaluating currently marketed hair supplements targeting the underlying root causes of thinning hair. All treatment regimens are commercially available nutraceutical hair growth supplements. 45 subjects will be enrolled into each of the 4 supplement groups. Subjects will undergo a baseline, baseline + 48 hours, 90 day, 90 day + 48 hours, 180 day and 180 day + 48 hours visit and will have compliance phone calls at Days 45 and 135. All subject data will be compared to baseline in paired comparison for each subject using a historical control.

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

181

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

    • California
      • Sacramento, California, Forenede Stater, 95815
        • Integrative Skin Science and Research

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 70 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ja

Køn, der er berettiget til at studere

Kvinde

Beskrivelse

Inclusion Criteria:

  1. Females of all Fitzpatrick skin, and hair types between 18-70 years of age with self-perceived thinning, confirmed by a dermatologist.
  2. Willing and able to adhere to the same dietary lifestyles for the duration of the study.
  3. Able to understand and sign an informed consent agreement and photo release form approved by the Institutional Review Board
  4. General good health, as determined by the Investigator or qualified sub-investigator.
  5. Willing and able to attend all study visits and comply with the test product daily instructions.
  6. Willing to use a mild non-medicated shampoo and conditioner for the duration of the study (medicated shampoo and conditioner refer to any prescription shampoo or conditioner as well as any over-the counter medicated shampoo or conditioner, such as those for treatment of dandruff or promoting hair growth).
  7. Willing and able to cooperate with the requirements of the study.
  8. Able to complete and understand the various questionnaires.

Exclusion Criteria:

  1. Individuals who are pregnant, planning a pregnancy, nursing, or within 1-year post-partum.
  2. Individuals who have experienced serious complications due to COVID-19 previously or during the study as determined by the investigator.
  3. Clinical diagnosis of hair loss disorder such as alopecia areata, or scarring forms of alopecia.
  4. Individuals who have had a history of any acute or chronic disease that could interfere with or increase the risk on study participation.
  5. Individuals who have had a history of any acute or chronic medical or hair condition that could affect study results, such as a history of disordered eating.
  6. Scalp hair loss on the treatment area, due to disease, injury, or medical therapy.
  7. Current skin disease (e.g., psoriasis, atopic dermatitis, skin cancer, eczema, sun damage, seborrheic dermatitis), infection, cuts, and/ or abrasions on the scalp or condition (e.g., sunburn, tattoos) on the treatment area that, in the opinion of the Investigator or qualified sub-investigator, might put the subject at risk or interfere with the study conduct or evaluations.
  8. History of surgical correction of hair loss on the scalp (i.e., hair transplant).
  9. Use of any products or devices purported to promote scalp hair growth (e.g., finasteride or minoxidil) within the 6 months prior to the Baseline Visit.
  10. Females who have recently (within the last 6 months) started the use of hormones for birth control or hormone replacement therapy (HRT). Women currently using hormones for birth control or HRT must have been on a stable dose (6 months or longer) in order to be eligible for the study (the initiation of HRT or birth control should not have been associated with the initiation of hair loss/thinning).
  11. History of malignancy (except cutaneous squamous cell carcinoma and basal cell carcinoma) or currently undergoing chemotherapy or radiation treatments.
  12. A known history of autoimmune thyroid disease, any other thyroid disorder/abnormality or other autoimmune disorders that in the opinion of the Investigator or qualified sub-investigator may interfere with the study treatment.
  13. A known history of unstable or chronic depression or bipolar disease or any other condition that may impact the subject's participation in the opinion of the investigator or qualified sub-investigator.
  14. A known allergy to any of the ingredients in the investigational product.
  15. Utilization of low-level lasers for hair growth in the last three months.
  16. Any condition that the Investigator thinks may put the subject at risk or interfere with their participation in the study or study results.
  17. Known history of or current iron deficiency, bleeding disorders or platelet dysfunction syndrome as well as subjects receiving anticoagulant therapy or smokers with usage >20 cigarettes/day as reported by the subject.
  18. Use of any medications or medicated shampoos that are known to potentially cause hair loss or affect hair growth, as determined by the Investigator or qualified sub-investigator.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Nutrafol Hair Growth Supplement

4 commercially available hair growth nutraceuticals will be evaluated. Treatment groups will be assigned according to the investigator's discretion. Efficacy comparisons will not be made across treatment groups.

Hair growth supplement for women ages 18 - 44. This product will be studied in the general women population and not postpartum women.

Hair growth supplement for women ages 18 - 44

Hair growth supplement for women ages 45 - 70

Hair growth supplement for women ages 18 - 44. This treatment group may also include subjects who do not follow a plant-based diet for purposes of extending the product claims beyond the initially studied demographic of women primarily adhering to a plant-based diet

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The percent change in hair growth rate at Day 180 relative to baseline (Day 0)
Tidsramme: 180 days

The percent change in hair growth rate at Day 180 relative to baseline (Day 0) using Canfield HairMetrix® non-invasive device.

180 days

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
The percent change in hair growth rate at Day 90 relative to baseline (Day 0)
Tidsramme: 90 Days

The percent change in hair growth rate at Day 90 relative to baseline (Day 0) as measured by the Canfield HairMetrix®.

90 Days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days
Tidsramme: 90 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 90 days as measured by the Canfield HairMetrix® compared to baseline.

90 days
The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days
Tidsramme: 180 days

The change in total hair count, terminal hairs, vellus hairs, anagen, and telogen hairs compared to baseline at 180 days as measured by the Canfield HairMetrix® compared to baseline.

180 days
The change in terminal to vellus ratio
Tidsramme: 90 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in terminal to vellus ratio
Tidsramme: 180 Days

The change in terminal to vellus ratio as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in anagen to telogen ratio
Tidsramme: 90 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in anagen to telogen ratio
Tidsramme: 180 Days

The change in terminal to vellus ratio per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in average number of hairs per follicular unit
Tidsramme: 90 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in average number of hairs per follicular unit
Tidsramme: 180 Days

The change in average number of hairs per follicular unit as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in total hair width per cm2
Tidsramme: 90 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in total hair width per cm2
Tidsramme: 180 Days

The change in total hair width per cm2 as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
The change in mean inter-follicular distance
Tidsramme: 90 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 90 days compared to baseline.

90 Days
The change in mean inter-follicular distance
Tidsramme: 180 Days

The change in mean inter-follicular distance as measured by the Canfield HairMetrix® at 180 days compared to baseline.

180 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 90 days
Tidsramme: 90 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 90 days

90 Days
Subjective assessments of change measured with Consumer Perception Questionnaire at 180 days
Tidsramme: 180 Days

Subjective assessments of change in hair growth and appearance measured with Consumer Perception Questionnaire at 180 days

180 Days

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

6. maj 2024

Primær færdiggørelse (Faktiske)

18. juni 2025

Studieafslutning (Faktiske)

18. juni 2025

Datoer for studieregistrering

Først indsendt

11. april 2024

Først indsendt, der opfyldte QC-kriterier

16. april 2024

Først opslået (Faktiske)

19. april 2024

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

16. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner